CN107735087B - 组蛋白脱乙酰酶抑制剂及其组合物和使用方法 - Google Patents

组蛋白脱乙酰酶抑制剂及其组合物和使用方法 Download PDF

Info

Publication number
CN107735087B
CN107735087B CN201680040059.0A CN201680040059A CN107735087B CN 107735087 B CN107735087 B CN 107735087B CN 201680040059 A CN201680040059 A CN 201680040059A CN 107735087 B CN107735087 B CN 107735087B
Authority
CN
China
Prior art keywords
pharmaceutically acceptable
compound
acceptable salt
membered
enantiomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680040059.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN107735087A (zh
Inventor
C·多明格斯
M·C·梅拉德
P·布莱斯亚
A·F·豪根
R·E·贾维斯
C·A·卢克赫斯特
E·A·萨维尔-斯冬斯
A·J·斯多特
A·范德波尔
M·沃尔
G·威沙特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CHDI Foundation Inc
Original Assignee
CHDI Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CHDI Foundation Inc filed Critical CHDI Foundation Inc
Publication of CN107735087A publication Critical patent/CN107735087A/zh
Application granted granted Critical
Publication of CN107735087B publication Critical patent/CN107735087B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
CN201680040059.0A 2015-05-07 2016-05-06 组蛋白脱乙酰酶抑制剂及其组合物和使用方法 Active CN107735087B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562158379P 2015-05-07 2015-05-07
US62/158,379 2015-05-07
PCT/US2016/031329 WO2016179550A1 (en) 2015-05-07 2016-05-06 Histone deacetylase inhibitors and compositions and methods of use thereof

Publications (2)

Publication Number Publication Date
CN107735087A CN107735087A (zh) 2018-02-23
CN107735087B true CN107735087B (zh) 2021-09-03

Family

ID=57218066

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680040059.0A Active CN107735087B (zh) 2015-05-07 2016-05-06 组蛋白脱乙酰酶抑制剂及其组合物和使用方法

Country Status (12)

Country Link
US (2) US10047073B2 (https=)
EP (1) EP3291809B1 (https=)
JP (1) JP6782255B2 (https=)
KR (1) KR20180002730A (https=)
CN (1) CN107735087B (https=)
AU (1) AU2016256917B2 (https=)
BR (1) BR112017023710B1 (https=)
CA (1) CA2984621C (https=)
EA (1) EA035592B1 (https=)
IL (1) IL255449B2 (https=)
MX (1) MX379817B (https=)
WO (1) WO2016179550A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016256917B2 (en) * 2015-05-07 2021-08-26 Chdi Foundation, Inc. Histone deacetylase inhibitors and compositions and methods of use thereof
MX378983B (es) 2015-05-07 2025-03-10 Chdi Foundation Inc Inhibidores de histona deacetilasa y composiciones y metodos para el uso de los mismos.
WO2017211650A1 (en) * 2016-06-09 2017-12-14 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
BR112019001229B1 (pt) * 2016-07-22 2022-11-16 Syngenta Participations Ag Composto derivado de oxadiazol, composição agroquímica compreendendo o mesmo, método para controlar ou impedir infestação de plantas úteis por microrganismos fitopatogênicos e uso do referido composto como fungicida
WO2018165520A1 (en) 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
WO2019219464A1 (en) 2018-05-15 2019-11-21 Basf Se Substituted trifluoromethyloxadiazoles for combating phytopathogenic fungi
KR102052844B1 (ko) 2019-01-31 2019-12-05 주식회사 아이스크림에듀 학습 분석 방법 및 시스템
KR102009034B1 (ko) 2019-01-31 2019-08-08 주식회사 아이스크림에듀 학습 분석을 기초로 정보를 제공하는 방법 및 시스템
AU2020321955A1 (en) 2019-07-30 2022-03-17 Eikonizo Therapapeutics, Inc. HDAC6 inhibitors and uses thereof
KR102232343B1 (ko) 2019-12-11 2021-03-26 주식회사 아이스크림에듀 인공지능 기반 맞춤형 학습 방법 및 시스템
KR102191672B1 (ko) 2019-12-20 2020-12-16 주식회사 아이스크림에듀 학습 분석 및 인공지능 기반 맞춤형 학습 방법 및 시스템
KR102191671B1 (ko) 2019-12-20 2020-12-16 주식회사 아이스크림에듀 소셜 러닝 및 e포트폴리오 기반 맞춤형 학습 방법 및 시스템
KR102197752B1 (ko) 2019-12-20 2021-01-04 주식회사 아이스크림에듀 맞춤형 자동 문항 생성을 통한 인공지능 기반 학습 방법 및 시스템
KR102191670B1 (ko) 2019-12-20 2020-12-16 주식회사 아이스크림에듀 문제은행 및 지식맵 기반 맞춤형 학습 방법 및 시스템
KR102258234B1 (ko) 2020-02-27 2021-05-31 주식회사 아이스크림에듀 인공지능 가정교사 인터페이스가 적용된 맞춤형 학습 방법 및 시스템
KR102258235B1 (ko) 2020-02-27 2021-05-31 주식회사 아이스크림에듀 실감 콘텐츠가 적용된 인공지능 기반의 맞춤형 학습 방법 및 시스템
KR102232344B1 (ko) 2020-02-27 2021-03-26 주식회사 아이스크림에듀 빅데이터 및 인공지능 기반의 맞춤형 학습 방법 및 시스템
CN111190006A (zh) * 2020-03-09 2020-05-22 上海市东方医院（同济大学附属东方医院） 组蛋白去乙酰化酶6在制备用于评估维持性腹膜透析患者腹膜功能的标志物中的用途
KR102222533B1 (ko) 2020-06-25 2021-03-05 주식회사 아이스크림미디어 고정형 웹 콘텐츠를 반응형 콘텐츠로 자동 변환하는 시스템 및 그 제어방법
KR20230049675A (ko) * 2020-08-07 2023-04-13 이탈파마코 에스.피.에이. 신규한 옥사디아졸-기반 선택적 hdac6 억제제
KR102248960B1 (ko) 2020-08-19 2021-05-07 주식회사 아이스크림에듀 인공지능 학습 플랫폼을 이용한 비즈니스 방법 및 시스템
TW202345813A (zh) 2022-04-08 2023-12-01 美商艾科尼佐療法股份有限公司 㗁二唑ｈｄａｃ６抑制劑及其用途
CN117430513A (zh) * 2023-10-27 2024-01-23 中昊(大连)化工研究设计院有限公司 环丙基胺的合成新方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101115742A (zh) * 2004-12-10 2008-01-30 P.安杰莱蒂分子生物学研究所 作为组蛋白脱乙酰基酶抑制剂的杂环衍生物
WO2013008162A1 (en) * 2011-07-08 2013-01-17 Novartis Ag Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1828171B1 (en) * 2004-12-10 2014-03-12 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Heterocycle derivatives as histone deacetylase (hdac) inhibitors
US8981084B2 (en) * 2010-01-13 2015-03-17 Tempero Pharmaceuticals, Inc. Oxadiazole HDAC inhibitors
AU2011205283B2 (en) 2010-01-13 2014-07-10 Tempero Pharmaceuticals, Inc. Compounds and methods
WO2013006408A1 (en) 2011-07-01 2013-01-10 Tempero Pharmaceuticals, Inc. Compounds and methods
WO2013009830A1 (en) * 2011-07-13 2013-01-17 Tempero Pharmaceuticals, Inc. Methods of treatment
WO2013009810A1 (en) 2011-07-13 2013-01-17 Tempero Pharmaceuticals, Inc. Methods of treatment
SI2750677T1 (sl) * 2011-08-30 2017-10-30 Chdi Foundation, Inc. Inhibitorji kinurenin-3-monooksigenaze, farmacevtski sestavki in postopki njihove uporabe
BR112014012815A8 (pt) 2011-11-28 2017-06-20 Novartis Ag derivados de trifluormetil-oxadiazol e uso dos mesmos no tratamento de doença
KR20150000882A (ko) * 2012-04-05 2015-01-05 씨에이치디아이 파운데이션, 인코포레이티드 키뉴레닌-3-모노산소첨가효소 억제제들, 약학 조성물들 및 이의 사용 방법
AU2016256917B2 (en) * 2015-05-07 2021-08-26 Chdi Foundation, Inc. Histone deacetylase inhibitors and compositions and methods of use thereof
MX378983B (es) 2015-05-07 2025-03-10 Chdi Foundation Inc Inhibidores de histona deacetilasa y composiciones y metodos para el uso de los mismos.
PL3328843T3 (pl) 2015-07-27 2023-02-27 Chong Kun Dang Pharmaceutical Corp. Związki będące pochodnymi 1,3,4 oksadiazolosulfonamidów jako inhibitor deacetylazy histonowej 6, oraz kompozycja farmaceutyczna je zawierająca
RU2695227C9 (ru) 2015-07-27 2020-03-04 Чонг Кун Данг Фармасьютикал Корп. Производные 1,3,4-оксадиазолсульфамида в качестве ингибитора гистондеацетилазы 6 и содержащая их фармацевтическая композиция
JP6491393B2 (ja) 2015-08-04 2019-03-27 チョン クン ダン ファーマシューティカル コーポレーション ヒストン脱アセチル化酵素６阻害剤としての１，３，４−オキサジアゾール誘導体化合物及びこれを含有する薬剤学的組成物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101115742A (zh) * 2004-12-10 2008-01-30 P.安杰莱蒂分子生物学研究所 作为组蛋白脱乙酰基酶抑制剂的杂环衍生物
WO2013008162A1 (en) * 2011-07-08 2013-01-17 Novartis Ag Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease
CN103764635A (zh) * 2011-07-08 2014-04-30 诺华股份有限公司 新的三氟甲基-噁二唑衍生物及其在疾病治疗中的用途

Also Published As

Publication number Publication date
HK1252489A1 (zh) 2019-05-24
AU2016256917B2 (en) 2021-08-26
EP3291809A4 (en) 2018-10-03
AU2016256917A1 (en) 2017-11-23
EP3291809A1 (en) 2018-03-14
US20160333001A1 (en) 2016-11-17
WO2016179550A1 (en) 2016-11-10
EP3291809B1 (en) 2021-08-25
IL255449B2 (en) 2023-07-01
IL255449B1 (en) 2023-03-01
BR112017023710B1 (pt) 2023-03-07
KR20180002730A (ko) 2018-01-08
CA2984621A1 (en) 2016-11-10
BR112017023710A2 (pt) 2018-07-31
JP2018515492A (ja) 2018-06-14
US20190185463A1 (en) 2019-06-20
IL255449A0 (en) 2017-12-31
EA201792255A1 (ru) 2018-06-29
MX2017014299A (es) 2018-08-09
US10047073B2 (en) 2018-08-14
EA035592B1 (ru) 2020-07-13
JP6782255B2 (ja) 2020-11-11
MX379817B (es) 2025-03-11
CA2984621C (en) 2023-09-26
CN107735087A (zh) 2018-02-23

Similar Documents

Publication Publication Date Title
CN107735087B (zh) 组蛋白脱乙酰酶抑制剂及其组合物和使用方法
CN107735088B (zh) 组蛋白脱乙酰酶抑制剂及其组合物和使用方法
US9783488B2 (en) Histone deacetylase inhibitors and compositions and methods of use thereof
US10106535B2 (en) Histone deacetylase inhibitors and compositions and methods of use thereof
MX2013008629A (es) Inhibidores de histona desacetilasa y composiciones y metodos para su uso.
HK1252487B (en) Histone deacetylase inhibitors and compositions and methods of use thereof
HK1252489B (en) Histone deacetylase inhibitors and compositions and methods of use thereof
BR112017023711B1 (pt) Inibidores de histona deacetilase e composições e métodos de uso dos mesmos

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant